Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

BACKGROUND. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in pati...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Kadakia, Kunal C., Snyder, Claire F., Kidwell, Kelley M., Seewald, Nicholas J., Flockhart, David A., Skaar, Todd C., Desta, Zereunesay, Rae, James M., Otte, Julie L., Carpenter, Janet S., Storniolo, Anna M., Hayes, Daniel F., Stearns, Vered, Henry, N. Lynn
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2016
Onderwerpen:
Breast Cancer
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861358/
https://ncbi.nlm.nih.gov/pubmed/27009936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0349
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items